Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03474549 · ClinicalTrials.gov registry record · NA

Treatment With Intent to Generate Endovascular Reperfusion

A NA study of Ischemic Stroke, sponsored by Rapid Medical.

Completed
Registry status
NA
Development phase
160
Enrollment target
17
Study locations

NCT03474549 is a NA study of Ischemic Stroke that has completed, run by Rapid Medical. The registered enrollment target is 160 participants, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03474549, a NA study of Ischemic Stroke, has completed, sponsored by Rapid Medical.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target
17
Study locations

Study Summary

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.

Conditions Studied

Ischemic Stroke

Interventions

  • DEVICE Tigertriever revascularization device

Study Locations (17)

Florida

  • Tenet Health - Coral Springs
  • Baptist Health Research Institute - Jacksonville
  • Baptist Health South Florida - Miami
  • University of Miami - Miami

California

  • UCLA medical center - Los Angeles
  • Los Robles - Thousand Oaks

New York

  • Maimonides Medical Center - Brooklyn
  • University of Buffalo - Buffalo

Ohio

  • Riverside Methodist Hospital - Columbus
  • Mercy Health - Toledo

Georgia

  • WellStar Research Institute - Marietta

Iowa

  • University of Iowa - Iowa City

Massachusetts

  • University of Massachusetts - Worcester

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2018-05-09
Est. Completion 2020-06-30
Phase NA

Sponsor

Rapid Medical

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03474549

The ClinicalTrials.gov registry entry for NCT03474549 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,461-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (89% lower). The listed sponsor is Rapid Medical, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which Tigertriever revascularization device is the first listed.

NCT03474549 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT03474549 about?

NCT03474549 is a clinical study titled "Treatment With Intent to Generate Endovascular Reperfusion". Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are cand...

What is the current status of trial NCT03474549?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2018-05-09. Estimated completion is 2020-06-30.

What conditions does trial NCT03474549 study?

This clinical trial studies the following conditions: Ischemic Stroke.

What interventions are being tested in trial NCT03474549?

The interventions under investigation include: Tigertriever revascularization device (DEVICE).

Who is sponsoring clinical trial NCT03474549?

This trial is sponsored by Rapid Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03474549 being conducted?

This trial has 17 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ischemic Stroke

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.